Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
OCS 
Oculis Holding AG Ordinary shares (OCS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/15/2025: OCS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $44.91
1 Year Target Price $44.91
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.48% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.20B USD | Price to earnings Ratio - | 1Y Target Price 44.91 |
Price to earnings Ratio - | 1Y Target Price 44.91 | ||
Volume (30-day avg) 7 | Beta 0.14 | 52 Weeks Range 14.00 - 23.08 | Updated Date 12/14/2025 |
52 Weeks Range 14.00 - 23.08 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8352.26% |
Management Effectiveness
Return on Assets (TTM) -33.35% | Return on Equity (TTM) -92.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1018798142 | Price to Sales(TTM) 1514.96 |
Enterprise Value 1018798142 | Price to Sales(TTM) 1514.96 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.47 | Shares Outstanding 57806909 | Shares Floating 39934746 |
Shares Outstanding 57806909 | Shares Floating 39934746 | ||
Percent Insiders 5.72 | Percent Institutions 39.48 |
About Oculis Holding AG Ordinary shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-02 | CEO & Director Dr. Riad Sherif M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://oculis.com |
Full time employees 49 | Website https://oculis.com | ||
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.